Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Data Source
2.2. Statistical Analysis
3. Results
3.1. Case-Control Propensity Score Matching
3.2. Characteristics of Colonic Diverticulosis in UC Patients
3.3. Ulcerative Colitis Patients with Concomitant Colonic Diverticulosis Have Prevalently a Mild Disease Course
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Ungaro, R.; Mehandru, S.; Allen, P.B.; Peyrin-Biroulet, L.; Colombel, J.-F. Ulcerative colitis. Lancet 2017, 389, 1756–1770. [Google Scholar] [CrossRef]
- Troncone, E.; Monteleone, G. The safety of non-biological treatments in Ulcerative Colitis. Expert Opin. Drug Saf. 2017, 16, 779–789. [Google Scholar] [CrossRef]
- Cuomo, R.; Barbara, G.; Pace, F.; Annese, V.; Bassotti, G.; Binda, G.A.; Casetti, T.; Colecchia, A.; Festi, D.; Fiocca, R.; et al. Italian consensus conference for colonic diverticulosis and diverticular disease. United Eur. Gastroenterol. J. 2014, 2, 413–442. [Google Scholar] [CrossRef] [Green Version]
- Rispo, A.; Pasquale, L.; Cozzolino, A.; Di Girolamo, E.; De Palma, G.D.; Grassia, R.; Compagna, A.; Chierchia, M.R.; Castiglione, F. Lower Prevalence of Diverticulosis in Patients with Ulcerative Colitis. Dis. Colon Rectum 2007, 50, 1164–1168. [Google Scholar] [CrossRef]
- Cassieri, C.; Pica, R.; Avallone, E.V.; Zippi, M.; Crispino, P.; De Nitto, D.; Paoluzi, P.; Brandimarte, G.; Lecca, P.G.; Elisei, W.; et al. Prevalence of Colonic Diverticulosis in Patients Affected by Ulcerative Colitis. J. Clin. Gastroenterol. 2016, 50 (Suppl. 1), S33–S35. [Google Scholar] [CrossRef]
- Lahat, A.; Avidan, B.; Bar-Meir, S.; Chowers, Y. Long-standing colonic inflammation is associated with a low prevalence of diverticuli in inflammatory bowel disease patients. Inflamm. Bowel Dis. 2007, 13, 733–736. [Google Scholar] [CrossRef] [Green Version]
- Kinnucan, J.; Tomal, J.; Rubin, D.T. U.S. Patients with Ulcerative Colitis Do Not Have a Decreased Risk of Diverticulosis. Inflamm. Bowel Dis. 2015, 21, 2154–2157. [Google Scholar] [CrossRef]
- Sultan, K.; Fields, S.; Panagopoulos, G.; Korelitz, B.I. The Nature of Inflammatory Bowel Disease in Patients With Coexistent Colonic Diverticulosis. J. Clin. Gastroenterol. 2006, 40, 317–321. [Google Scholar] [CrossRef]
- Nascimbeni, R.; Casiraghi, S.; Cannatelli, R.; Lanzarotto, F.; Casella, C.; Ricci, C.; Villanacci, V.; Portolani, N.; Moneghini, D. Ulcerative colitis and the aging-related development of colonic diverticula. Int. J. Color. Dis. 2018, 33, 1277–1283. [Google Scholar] [CrossRef]
- Maaser, C.; Sturm, A.; Vavricka, S.R.; Kucharzik, T.; Fiorino, G.; Annese, V.; Calabrese, E.; Baumgart, D.C.; Bettenworth, D.; Borralho Nunes, P.; et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohns Colitis 2019, 13, 144–164. [Google Scholar]
- Nasef, N.A.; Mehta, S. Role of Inflammation in Pathophysiology of Colonic Disease: An Update. Int. J. Mol. Sci. 2020, 21, 4748. [Google Scholar] [CrossRef]
- Di Mario, F.; Miraglia, C.; Cambiè, G.; Violi, A.; Nouvenne, A.; Franceschi, M.; Brandimarte, G.; Elisei, W.; Picchio, M.; Tursi, A. Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon. J. Investig. Med. 2018, 67, 767–770. [Google Scholar] [CrossRef]
- Tursi, A.; Scarpignato, C.; Strate, L.L.; Lanas, A.; Kruis, W.; Lahat, A.; Danese, S. Colonic diverticular disease. Nat. Rev. Dis. Prim. 2020, 6, 1–23. [Google Scholar] [CrossRef]
- Mencarelli, A.; Renga, B.; Palladino, G.; Claudio, D.; Ricci, P.; Distrutti, E.; Barbanti, M.; Baldelli, F.; Fiorucci, S. Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. Eur. J. Pharmacol. 2011, 668, 317–324. [Google Scholar] [CrossRef]
- Cheng, J.; Shah, Y.M.; Ma, X.; Pang, X.; Tanaka, T.; Kodama, T.; Krausz, K.W.; Gonzalez, F.J. Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation. J. Pharmacol. Exp. Ther. 2010, 335, 32–41. [Google Scholar] [CrossRef] [Green Version]
- Manõsa, M.; Calafat, M.; De Francisco, R.; García, C.; Casanova, M.J.; Huelin, P.; Calvo, M.; Tosca, J.; Fernández-Salazar, L.; Arajol, C.; et al. Phenotype and natural history of elderly onset inflammatory bowel disease: A multicentre, case-control study. Aliment. Pharmacol. Ther. 2018, 47, 605–614. [Google Scholar] [CrossRef] [Green Version]
CHARACTERISTICS | UC with Diverticulosis |
---|---|
Number of patients | 92 |
Timing of diagnosis of diverticular disease compared to that of UC n (%) | |
Previous | 14 (15.2) |
Subsequent | 57 (61.9) |
Concomitant | 21 (22.8) |
Diverticula localization n (%) | |
Left colon | 70 (76.1) |
Whole colon | 22 (23.9) |
History of acute diverticulitis n (%) | 11 (11.6) |
Surgery for diverticular disease n (%) | 4 (4.2) |
CHARACTERISTICS | UC with Diverticulosis | UC without Diverticulosis | p-Value |
---|---|---|---|
Number of patients | 92 | 153 | |
Gender female n (%) | 37 (40.2) | 46 (30.0) | 0.2 |
Median Age (range) years | 71 (48-92) | 67 (48-84) | 0.89 |
Smoking habit n (%) | |||
Current smokers | 10 (10.8) | 11 (7.1) | 0.11 |
Former smokers | 32 (34.7) | 46 (30.06) | |
Appendectomy n (%) | 10 (10.8) | 6 (3.9) | 0.056 |
Mean disease’s duration (years) | 19 | 16 | 0.008 |
UC extent n (%) | |||
E1 | 19 (20.6) | 14 (9.1) | <0.001 |
E2 | 48 (52.1) | 69 (45.0) | 0.068 |
E3 | 25 (27.1) | 70 (45.7) | <0.001 |
Steroid dependence n (%) | 8 (8.6) | 48 (31.3) | <0.001 |
Steroid refractoriness n (%) | 1 (1.0) | 7 (4.5) | 0.09 |
Need of ISS n (%) | 9 (9.7) | 37 (24.1) | 0.007 |
Need of biologics n (%) | 3 (3.2) | 26 (16.9) | <0.001 |
>1 relapse/year n (%) | 6 (6.5) | 16 (10.4) | 0.013 |
Hospitalization n (%) | |||
0 | 64 (69.5) | 113 (74.3) | 0.44 |
≥1 | 28 (30.4) | 40 (26.1) | |
History of colorectal surgery n (%) | 13 (14.1) | 13 (8.4) | 0.068 |
EIM n (%) | 12 (13.0) | 32 (20.9) | 0.17 |
Years of follow-up median (range) | 7 (1–19) | 5 (1–19) | 0.9 |
VARIABLES | UC with Diverticulosis | UC without Diverticulosis | p-Value |
---|---|---|---|
Number of patients | 92 | 153 | |
UC extent E3 n (%) | 25 (27.1) | 70 (45.7) | <0.001 |
Steroid dependence n (%) | 8 (8.6) | 48 (31.3) | 0.028 |
Need of ISS n (%) | 9 (9.7) | 37 (24.1) | 0.51 |
Need of biologics n (%) | 3 (3.2) | 26 (16.9) | 0.31 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marafini, I.; Salvatori, S.; Rocchetti, I.; Alfieri, N.; Scarozza, P.; Calabrese, E.; Biancone, L.; Monteleone, G. Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis. J. Clin. Med. 2021, 10, 1192. https://doi.org/10.3390/jcm10061192
Marafini I, Salvatori S, Rocchetti I, Alfieri N, Scarozza P, Calabrese E, Biancone L, Monteleone G. Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis. Journal of Clinical Medicine. 2021; 10(6):1192. https://doi.org/10.3390/jcm10061192
Chicago/Turabian StyleMarafini, Irene, Silvia Salvatori, Irene Rocchetti, Norma Alfieri, Patrizio Scarozza, Emma Calabrese, Livia Biancone, and Giovanni Monteleone. 2021. "Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis" Journal of Clinical Medicine 10, no. 6: 1192. https://doi.org/10.3390/jcm10061192
APA StyleMarafini, I., Salvatori, S., Rocchetti, I., Alfieri, N., Scarozza, P., Calabrese, E., Biancone, L., & Monteleone, G. (2021). Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis. Journal of Clinical Medicine, 10(6), 1192. https://doi.org/10.3390/jcm10061192